EMAIL TO A FRIEND COMMENT

 

FDA Approves First Supplemental Test for Chagas Disease Spread by Blood Parasites and Other Means


The FDA approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to Trypanosoma cruzi (T. cruzi). T. cruzi causes Chagas disease, a serious and potentially fatal parasitic infection.

 

Chagas disease is mainly spread by blood-sucking insects infected with T. cruzi. Chagas disease can also be spread through blood transfusion, organ transplants, and from mother to unborn child. The estimated number of persons living in the United States infected with T. cruzi, and at risk for developing Chagas disease, is 300,000 or more.

 

The test, called the ABBOTT ESA Chagas [Trypanosoma cruzi (E. coli, Recombinant) Antigen], is an in vitro enzyme strip assay for the qualitative detection of antibodies to T. cruzi. There are currently two donor screening tests licensed to detect antibodies to T. cruzi. However, this will be the first test licensed as a supplemental test.

 

More than 5,000 donors with positive test results on a screening test have been identified since national screening of the blood supply was instituted in early 2007.


See the FDA Approval

 

 

REPRINTS & PERMISSIONS COMMENT